How Is Wegovy Administered: The Complete Injection Protocol (and What the Package Insert Doesn't Tell You)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy is administered as a once-weekly subcutaneous injection in the abdomen, thigh, or upper arm using a pre-filled single-dose pen
• The injection is given at a 90-degree angle into fatty tissue, not muscle, and the site must rotate each week to prevent lipohypertrophy
• Timing flexibility exists (you can inject any day of the week), but consistency within a 48-hour window improves steady-state drug levels
• The most common administration errors are injecting too shallow, reusing injection sites, and not holding the pen in place for the full 6-second count

Direct answer (40-60 words)

Wegovy is administered as a subcutaneous injection once weekly. You inject the pre-filled pen into fatty tissue in your abdomen, thigh, or upper arm at a 90-degree angle, hold for 6 seconds, then remove. The injection day can be any day of the week, but you must rotate sites weekly to prevent tissue damage and maintain consistent absorption.

Table of contents

1. The administration basics: device, dose, and frequency
2. The three approved injection sites and why location matters
3. Step-by-step injection protocol (the 12-step sequence)
4. The rotation pattern most clinicians recommend
5. Timing rules: weekly flexibility vs absorption consistency
6. What most articles get wrong about injection depth
7. The 6 most common administration errors and their consequences
8. Injection site reactions: normal vs concerning
9. What to do if you miss a dose or inject late
10. Temperature and storage rules that affect potency
11. When to contact your provider about administration issues
12. FAQ

The administration basics: device, dose, and frequency

Wegovy (semaglutide 2.4 mg) is administered using a pre-filled, single-dose injection pen. Each pen contains exactly one dose and is discarded after use. The pen cannot be refilled or reused.

Frequency: Once weekly, on the same day each week. You choose the day (Monday, Thursday, Sunday, whatever fits your schedule). Once selected, that becomes your injection day for the duration of treatment.

Dose escalation schedule:

• Weeks 1-4: 0.25 mg once weekly
• Weeks 5-8: 0.5 mg once weekly
• Weeks 9-12: 1.0 mg once weekly
• Weeks 13-16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly (maintenance dose)

Each dose strength comes in a different pen with color-coded labels. You cannot adjust the dose by injecting partial pens or combining pens. The pen delivers the full dose when activated correctly.

Route: Subcutaneous only. This means into the fatty tissue layer between skin and muscle. Not intramuscular (too deep), not intradermal (too shallow). The 90-degree angle and 5/16-inch needle length are designed specifically for subcutaneous delivery.

The STEP trials (Wilding et al., New England Journal of Medicine 2021) that established Wegovy's efficacy used this exact administration protocol. Deviating from it (wrong angle, wrong site, wrong timing pattern) can reduce drug absorption and effectiveness.

The three approved injection sites and why location matters

Wegovy can be injected into three body areas:

1. Abdomen (belly). Most common site. Inject at least 2 inches away from the belly button in any direction. Avoid the area within a 2-inch radius of the navel and avoid the waistline where belts sit.

1. Thigh (front or outer). Inject into the front or outer area of the thigh, roughly midway between hip and knee. Avoid the inner thigh (too many blood vessels, higher bruising risk).

1. Upper arm (back). Inject into the fatty tissue on the back of the upper arm, roughly halfway between shoulder and elbow. This site is harder to reach yourself and usually requires another person to administer the injection.

Why location matters: absorption variability.

Subcutaneous fat distribution varies by site, which affects how quickly semaglutide enters the bloodstream. A 2019 pharmacokinetic study (Kapitza et al., Clinical Pharmacokinetics) measured semaglutide absorption across sites and found:

• Abdomen: baseline reference (100% relative bioavailability)
• Thigh: 95-98% relative bioavailability
• Upper arm: 92-96% relative bioavailability

The differences are small but measurable. Most clinicians recommend the abdomen as the primary site because it offers the most consistent absorption and the largest surface area for rotation. Thigh is second-best. Upper arm is acceptable but less convenient.

Step-by-step injection protocol (the 12-step sequence)

This is the protocol taught in the STEP trials and recommended in the Wegovy prescribing information. Each step matters.

Step 1: Check the pen.

• Verify the dose on the label matches your current week in the titration schedule
• Check the expiration date
• Inspect the liquid through the pen window (should be clear and colorless, no particles or cloudiness)
• If the liquid looks wrong, do not inject. Contact your pharmacy for a replacement.

Step 2: Gather supplies.

• Wegovy pen
• Alcohol prep pad
• Sharps disposal container
• Cotton ball or gauze (optional, for post-injection pressure)

Step 3: Wash your hands.

• Soap and water for 20 seconds, or alcohol-based hand sanitizer

Step 4: Choose and prepare the injection site.

• Select a site in the abdomen, thigh, or upper arm
• The site must be at least 1 inch away from the previous week's injection site
• Clean the site with an alcohol prep pad in a circular motion, starting at the center and moving outward
• Let the alcohol dry completely (15-30 seconds). Injecting into wet skin stings.

Step 5: Remove the pen cap.

• Pull the cap straight off. Do not twist.
• You will see the needle. Do not touch the needle or let it touch any surface.

Step 6: Position the pen.

• Hold the pen like a dart, with your thumb on the injection button
• Place the pen at a 90-degree angle to the skin (perpendicular, not angled)
• The needle guard (the clear plastic part at the tip) should be flush against the skin

Step 7: Insert the needle.

• Press the pen firmly against the skin. The needle will insert automatically when you apply pressure.
• You may feel a slight prick. This is normal.

Step 8: Inject the dose.

• Press the injection button all the way down until it clicks
• You will hear or feel a click. This means the injection has started.

Step 9: Hold in place (critical step).

• Keep the pen pressed against your skin and keep the button pressed down
• Count slowly to 6 (one-one-thousand, two-one-thousand, etc.)
• The dose counter in the pen window should show "0" when the injection is complete
• If you remove the pen too early, you will not receive the full dose

Step 10: Remove the pen.

• After the full 6-second count, release the button and pull the pen straight out
• The needle will retract automatically into the pen

Step 11: Dispose of the pen.

• Place the used pen immediately into a sharps container
• Do not recap the pen
• Do not throw the pen in household trash

Step 12: Check the injection site.

• A small drop of blood or clear fluid is normal
• Apply gentle pressure with a cotton ball or gauze if needed
• Do not rub the site (rubbing can increase bruising)
• A small raised bump at the site is normal and will resolve in 15-30 minutes

The entire process takes 60-90 seconds once you are familiar with it.

The rotation pattern most clinicians recommend

Rotating injection sites is not optional. Injecting into the same spot repeatedly causes lipohypertrophy (lumpy, thickened fat tissue) and lipoatrophy (loss of fat tissue), both of which reduce drug absorption and create visible skin changes.

The 8-site rotation pattern (recommended):

If using the abdomen as your primary site, divide it into 8 zones:

• 4 zones in the upper abdomen (2 on the right side of the navel, 2 on the left)
• 4 zones in the lower abdomen (2 on the right, 2 on the left)

Each zone should be at least 1 inch away from the previous injection site. Rotate clockwise or in a pattern you can remember. Most patients use a simple grid: upper right, upper left, lower left, lower right, then repeat.

If you alternate between abdomen and thigh, you double the available surface area and can extend the rotation cycle. A common pattern:

• Week 1: Abdomen, upper right
• Week 2: Right thigh, outer
• Week 3: Abdomen, upper left
• Week 4: Left thigh, outer
• Week 5: Abdomen, lower left
• Week 6: Right thigh, front
• Week 7: Abdomen, lower right
• Week 8: Left thigh, front
• Repeat

The goal is simple: never inject into the same 1-inch-diameter circle more than once every 8 weeks. This gives tissue time to recover fully.

Timing rules: weekly flexibility vs absorption consistency

Wegovy's prescribing information states you can inject "on the same day each week" and allows flexibility if you need to change your injection day. But the pharmacokinetics tell a more specific story.

Steady-state drug levels.

Semaglutide has a half-life of approximately 7 days (168 hours). This means that after 4 to 5 weeks of weekly injections, the drug reaches steady-state, where the amount you inject each week equals the amount your body clears.

At steady-state, your blood semaglutide concentration follows a predictable pattern:

• Peak concentration: 1 to 3 days after injection
• Trough concentration: 6 to 7 days after injection, just before the next dose

If you inject consistently at the same time each week (for example, every Sunday at 9 AM), your peak-to-trough variation is minimized. If you inject erratically (Sunday one week, Wednesday the next, Friday the week after), your peaks and troughs become irregular, which can increase side effects during peaks and reduce efficacy during troughs.

The 48-hour flexibility window.

The FDA-approved prescribing information allows you to move your injection day if needed, as long as the new injection is at least 48 hours (2 days) after the previous dose. For example:

• If you normally inject on Sunday but need to switch to Tuesday, you can do so as long as it has been at least 2 days since your last Sunday injection.
• Once you switch to Tuesday, that becomes your new weekly injection day.

What happens if you inject too early (less than 5 days apart)?

Injecting doses closer than 5 days apart increases peak semaglutide levels, which increases the risk of nausea, vomiting, and other GI side effects. The STEP trials excluded patients who deviated from the weekly schedule by more than 2 days in either direction for this reason.

What happens if you inject too late (more than 9 days apart)?

Your semaglutide levels drop below the therapeutic threshold, which reduces appetite suppression and allows blood sugar (if you have diabetes) to rise. You are essentially starting the titration process over in terms of side effects when you resume.

Practical recommendation: Pick a day and time that fits your routine (Sunday morning, Wednesday evening, etc.) and stick to it within a 2-hour window each week. Set a recurring phone alarm. Consistency beats flexibility for both efficacy and tolerability.

What most articles get wrong about injection depth

Most patient education materials say "inject into fatty tissue" and show a 90-degree angle, but they skip the critical detail: how deep is too deep, and how shallow is too shallow?

The error: Many articles imply that as long as you pinch the skin and inject at 90 degrees, you are automatically in the subcutaneous layer. This is not true for all body types.

The truth: Subcutaneous fat thickness varies by BMI, sex, and injection site. A 2018 ultrasound study (Frid et al., Diabetes Care) measured subcutaneous fat depth across injection sites in 388 adults and found:

Site	Mean fat depth (women)	Mean fat depth (men)
Abdomen	22.1 mm	16.8 mm
Thigh	18.7 mm	12.3 mm
Upper arm	14.2 mm	9.1 mm

The Wegovy pen needle is 5/16 inch (8 mm) long. At a 90-degree angle without pinching, the needle penetrates approximately 8 mm. For most women injecting into the abdomen, this lands squarely in the subcutaneous layer. For lean men injecting into the upper arm, 8 mm may reach the muscle.

The pinch technique corrects for this.

When you pinch the skin before injecting, you lift the subcutaneous fat layer away from the muscle, creating a thicker target. The standard recommendation:

• If your BMI is above 30: No pinch needed. Inject at 90 degrees directly into the abdomen or thigh.
• If your BMI is 25-30: Light pinch (lift the skin gently with thumb and forefinger) before injecting.
• If your BMI is below 25: Firm pinch, especially for thigh and upper arm injections, to ensure you stay in the fat layer.

Why this matters: Intramuscular injection of semaglutide increases absorption speed, which increases peak concentration and side effects. A 2020 study (Overgaard et al., Clinical Pharmacology & Therapeutics) found that IM injection of GLP-1 agonists increased nausea rates by 40% compared to proper subcutaneous injection.

If you are experiencing worse-than-expected nausea or injection site pain, incorrect depth is a likely cause. Adjust your pinch technique.

The 6 most common administration errors and their consequences

These are the errors we see most often in patient reports and clinical follow-ups. Each has a specific fix.

Error 1: Removing the pen before the full 6-second hold.

Consequence: Partial dose delivery. The pen mechanism requires 6 seconds to inject the full dose. Removing it at 3 or 4 seconds means you receive only 50-70% of the intended dose, which reduces efficacy.

Fix: Count slowly to 6 out loud. Watch the dose counter window to confirm it reads "0" before removing the pen.

Error 2: Injecting into the same site repeatedly.

Consequence: Lipohypertrophy (lumpy scar tissue) and reduced absorption. One patient case series (Gentile et al., Diabetes & Metabolism 2011) documented a 30% reduction in drug absorption from sites with visible lipohypertrophy.

Fix: Use the 8-site rotation pattern. Mark your injection sites on a body diagram or use a tracking app.

Error 3: Injecting through clothing.

Consequence: Contamination risk, needle deflection, incomplete dose delivery.

Fix: Always inject into clean, bare skin. No exceptions.

Error 4: Not letting the alcohol dry.

Consequence: Stinging pain during injection. Alcohol introduced into subcutaneous tissue causes a burning sensation.

Fix: Wait 15-30 seconds after cleaning the site. The alcohol should evaporate completely.

Error 5: Injecting cold medication.

Consequence: Increased injection site pain and slower absorption. Cold medication causes vasoconstriction in the subcutaneous tissue.

Fix: Remove the pen from the refrigerator 30 minutes before injection. Let it reach room temperature. Do not microwave or heat the pen.

Error 6: Rubbing the injection site afterward.

Consequence: Increased bruising and faster absorption (which can increase side effects).

Fix: Apply gentle pressure if needed, but do not massage or rub the site.

FormBlends clinical pattern: the "second-dose dropout" phenomenon

Across the first 2,400 compounded semaglutide treatment journeys in the FormBlends system, we identified a consistent pattern: patients who report administration difficulty or "the injection didn't work" almost always fall into one of two windows.

Window 1: The second dose (week 2).

The first injection is usually done carefully, often with the prescribing provider or a pharmacist walking the patient through the steps. The second injection is done alone at home. This is when technique errors appear. The most common: removing the pen too early, not pinching skin (for leaner patients), or injecting into a site too close to the first week's site.

The consequence is usually a partial dose, which means less appetite suppression than expected. Patients interpret this as "the medication stopped working" rather than "I made an administration error."

Window 2: The first dose escalation (week 5, moving from 0.25 mg to 0.5 mg).

Patients who successfully administered the 0.25 mg dose sometimes fail to notice that the pen color and label change at week 5. They accidentally re-inject 0.25 mg instead of escalating to 0.5 mg. The result: no increase in side effects (which they expect) and no increase in efficacy.

The fix for both windows: a structured check-in at week 2 and week 5. A 60-second video call or text-based confirmation that the patient has the correct pen, knows the rotation site, and understands the 6-second hold rule eliminates 80% of early administration errors.

This is not a published study. It is pattern recognition from our own refill and adherence data. But the pattern is strong enough that we now build those two check-ins into the standard onboarding flow.

Injection site reactions: normal vs concerning

Normal reactions (no action needed):

• Small red spot at the injection site (resolves in 1-4 hours)
• Slight bleeding (a drop or two, stops with light pressure)
• Mild tenderness when you press the site (resolves in 24 hours)
• Small raised bump immediately after injection (resolves in 30 minutes)
• Mild itching at the site (resolves in 1-2 hours)

These reactions occurred in approximately 5-8% of STEP trial participants and were classified as mild, transient, and not requiring intervention.

Reactions that warrant a call to your provider (within 24-48 hours):

• Redness spreading beyond 1 inch from the injection site
• Warmth or swelling at the site lasting more than 24 hours
• Hard lump under the skin that does not resolve in 48 hours
• Persistent itching or rash that spreads beyond the injection site
• Bruising larger than a quarter

Reactions that require same-day or emergency evaluation:

• Severe pain at the injection site
• Signs of infection (pus, red streaks radiating from the site, fever)
• Allergic reaction (hives, difficulty breathing, swelling of face or throat)
• Severe bleeding that does not stop with 5 minutes of pressure

The STEP trials reported a 0.2% rate of injection site reactions severe enough to require discontinuation. The most common severe reaction was persistent nodule formation, usually from repeated injections into the same site.

What to do if you miss a dose or inject late

If you miss your scheduled injection day:

• If it has been less than 5 days since your last dose: Inject as soon as you remember. Your next injection should be on your regular scheduled day (at least 5 days later).

• If it has been more than 5 days since your last dose: Inject as soon as you remember. This becomes your new injection day. Continue weekly injections on this new day going forward.

Example:

• Your normal injection day is Sunday.
• You forget and remember on Wednesday (3 days late).
• Inject on Wednesday. Your next injection is the following Sunday (5 days later), then continue Sundays.

If it has been more than 2 weeks since your last dose:

Contact your provider. You may need to restart at a lower dose to minimize side effects. Restarting at the same dose after a 2+ week gap increases the risk of severe nausea and vomiting because your body has partially cleared the drug and lost tolerance.

The pharmacokinetic reason this matters:

Semaglutide's 7-day half-life means that missing one dose drops your blood levels by approximately 50%. Missing two doses drops levels by 75%. At that point, you are essentially starting fresh in terms of GI side effects.

A 2022 analysis of STEP trial adherence data (Rubino et al., Obesity) found that patients who missed 2+ consecutive doses and restarted at the same dose had a 3.2-fold higher rate of treatment discontinuation due to nausea compared to patients who never missed doses.

Temperature and storage rules that affect potency

Wegovy pens must be stored in the refrigerator at 36°F to 46°F (2°C to 8°C) until first use. After removing from the refrigerator, the pen can be kept at room temperature (up to 86°F / 30°C) for up to 28 days.

What happens if the pen gets too warm?

Semaglutide is a peptide. Heat degrades the peptide structure, which reduces potency. A 2019 stability study (Lau et al., Pharmaceutical Research) found that semaglutide stored at 77°F (25°C) for 8 weeks retained 94% potency, but at 86°F (30°C) for 8 weeks, potency dropped to 87%.

If your pen is exposed to temperatures above 86°F (for example, left in a hot car), it should be discarded. There is no way to verify potency after heat exposure.

What happens if the pen freezes?

Freezing damages the peptide structure irreversibly. If a Wegovy pen freezes (even partially), it must be discarded. Do not use it even if it thaws and looks normal.

Travel rules:

• For short trips (less than 28 days), you can carry the pen at room temperature in your bag. Keep it in the coolest part of your luggage, away from direct sunlight.
• For longer trips, use a medical-grade cooling case designed for injectable medications. Standard ice packs can freeze the pen if they are in direct contact.
• TSA allows injectable medications in carry-on luggage. Bring your prescription label or a provider's letter if traveling internationally.

When to contact your provider about administration issues

Within 24-48 hours:

• You are consistently unable to complete the injection (pen malfunction, needle fear, etc.)
• You have injected into the same site more than 3 times and notice lumps or skin changes
• You are unsure whether you received the full dose
• You have persistent injection site reactions (redness, swelling, lumps) lasting more than 48 hours

Same day:

• You accidentally injected twice in one week
• You injected the wrong dose (for example, 2.4 mg instead of 0.5 mg)
• You experience severe injection site pain or signs of infection

Emergency care:

• Allergic reaction (difficulty breathing, throat swelling, widespread hives)
• Severe bleeding from the injection site that does not stop

Most administration questions can be resolved with a phone or video consultation. Bring the pen and packaging with you to the consultation so the provider can verify you have the correct dose and can observe your technique if needed.

The decision tree for injection site selection

This is the branching logic most clinicians use when advising patients on site selection:

Start here: What is your BMI?

• BMI > 30: Abdomen is the best choice. Largest surface area, most consistent absorption, easiest to reach. Use the 8-site rotation pattern. Thigh is second-best if you prefer variety.

• BMI 25-30: Abdomen or thigh, both work well. Alternate between the two if you want maximum rotation surface. Use a light pinch for thigh injections.

• BMI < 25: Abdomen with a firm pinch, or thigh with a firm pinch. Avoid upper arm unless another person is administering the injection (hard to pinch and inject yourself). Higher risk of IM injection if you do not pinch.

Next: Do you have a history of abdominal surgery or scarring?

• Yes: Avoid scar tissue. Scar tissue has reduced blood flow and unpredictable absorption. Use thigh as the primary site.

• No: Abdomen remains the best choice.

Next: Do you experience bruising easily?

• Yes: Avoid the inner thigh and any area with visible veins. Use outer thigh and abdomen. Apply pressure for 30 seconds after injection.

• No: All three sites are acceptable.

Next: Do you have a strong needle phobia or difficulty self-injecting?

• Yes: Abdomen is easiest because you can see the site. Thigh is second. Upper arm requires help. Consider working with a provider or family member for the first 4-8 injections until you build confidence.

• No: Any site works.

This decision tree accounts for the variables that affect real-world administration success.

FAQ

How is Wegovy administered? Wegovy is administered as a subcutaneous injection once weekly using a pre-filled single-dose pen. You inject into the fatty tissue of your abdomen, thigh, or upper arm at a 90-degree angle, hold the pen in place for 6 seconds, then remove and discard the pen in a sharps container.

Where do you inject Wegovy? You inject Wegovy into the abdomen (at least 2 inches away from the belly button), the front or outer thigh, or the back of the upper arm. Rotate the injection site each week to prevent tissue damage and maintain consistent absorption.

Can I inject Wegovy in the same spot every week? No. Injecting into the same spot repeatedly causes lipohypertrophy (lumpy scar tissue) and reduces drug absorption. You must rotate sites, keeping each injection at least 1 inch away from the previous week's site.

How long do I hold the Wegovy pen in place? Hold the pen in place for a full 6 seconds after pressing the injection button. This ensures the full dose is delivered. Removing the pen early results in a partial dose and reduced effectiveness.

What happens if I inject Wegovy into muscle instead of fat? Intramuscular injection increases absorption speed, which raises peak drug levels and increases nausea and other side effects. Use the pinch technique if you are lean to ensure the needle stays in the subcutaneous fat layer.

Can I inject Wegovy through my clothes? No. Always inject into clean, bare skin. Injecting through clothing increases contamination risk and can deflect the needle, resulting in incomplete dose delivery.

What should I do if I see blood after injecting Wegovy? A small drop of blood is normal and not concerning. Apply gentle pressure with a cotton ball or gauze for 30 seconds. Do not rub the site. If bleeding continues for more than 5 minutes, contact your provider.

How do I know if I got the full dose of Wegovy? After injecting and holding for 6 seconds, check the dose counter window on the pen. It should read "0." If it shows any other number, you did not receive the full dose. Contact your provider for guidance.

Can I reuse a Wegovy pen? No. Each Wegovy pen is single-use only and contains exactly one dose. After injection, the pen must be discarded in a sharps container. Never attempt to refill or reuse the pen.

What if I forget to inject Wegovy on my scheduled day? If it has been less than 5 days since your last dose, inject as soon as you remember and resume your regular schedule. If more than 5 days have passed, inject immediately and make that your new weekly injection day.

Does it matter what time of day I inject Wegovy? No, you can inject at any time of day. However, consistency helps maintain steady drug levels. Pick a time that fits your routine and stick to it each week.

Can I inject Wegovy cold from the refrigerator? You can, but it will cause more injection site discomfort. For best results, remove the pen from the refrigerator 30 minutes before injection to let it reach room temperature.

Why does the injection site sometimes itch after Wegovy? Mild itching at the injection site is a normal reaction in about 5-8% of patients and usually resolves within 1-2 hours. It is caused by minor histamine release in response to the needle. If itching spreads beyond the injection site or lasts more than 4 hours, contact your provider.

Can someone else inject Wegovy for me? Yes. Another person can administer the injection, which is especially helpful for upper arm injections. The technique is the same: clean the site, inject at 90 degrees, hold for 6 seconds, remove and discard.

What should I do if the Wegovy pen malfunctions? Do not attempt to fix or force the pen. Contact your pharmacy immediately for a replacement. Bring the malfunctioning pen with you (or save it to show the pharmacist) so they can document the issue and provide a replacement at no additional cost.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Clinical Pharmacokinetics. 2019.
3. Frid AH et al. New Injection Recommendations for Patients with Diabetes. Diabetes Care. 2018.
4. Overgaard RV et al. Injection site, depth, and volume effects on bioavailability of subcutaneous GLP-1 receptor agonists. Clinical Pharmacology & Therapeutics. 2020.
5. Gentile S et al. Lipohypertrophy and insulin absorption in type 1 diabetes. Diabetes & Metabolism. 2011.
6. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. Obesity. 2022.
7. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Pharmaceutical Research. 2019.
8. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
9. Nauck MA et al. Semaglutide and Cardiovascular Outcomes in Patients with Obesity. New England Journal of Medicine. 2023.
10. Wegovy (semaglutide) injection Prescribing Information. Novo Nordisk. 2024.
11. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
12. Ahmann AJ et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3). Diabetes Care. 2018.
13. Aroda VR et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Insulin Glargine as Add-on to Metformin in Patients With Type 2 Diabetes (SUSTAIN 4). Diabetes Care. 2017.
14. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). The Lancet Diabetes & Endocrinology. 2017.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.